BESPOKE Study of ctDNA guided therapy in colorectal cancer (CRC)

Signatera detects and tracks circulating tumor DNA (ctDNA) using a personalized, tumor-informed assay.


First prospective, multi-center clinical study examining the role of ctDNA in:

MRD Assessment | Adjuvant Treatment Guidance | Recurrence Monitoring

Our Goal:

BESPOKE CRC study seeks to quantify the impact on treatment decisions and outcomes based on the results of SignateraTM residual disease test (MRD).

Signatera Test:

Signatera is a tumor informed ctDNA assay for tracking 16 tumor-specific mutations in the blood for MRD determination and molecular monitoring.


BESPOKE CRC will measure changes in treatment decisions and clinical outcomes based on the use of Signatera in patients with stage II and III colorectal cancer. The study will enroll at least 1,000 patients. Natera and its collaborators will collect clinical utility and outcomes data on enrolled patients for two years.

Study sites:

>50 sites will be selected


Multicenter clinical trials will begin enrollment in March 2020


Budget will be sponsored by Natera’s clinical trials department, with budget for Institutional Review Board (IRB) approval, on-site coordination, data collection, and analysis.